INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 12 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,232,000 | 0.0% | 18,590,000 | 0.0% | 0.14% | -12.7% |
| Q4 2021 | $11,232,000 | -8.9% | 18,590,000 | -9.7% | 0.16% | -6.2% |
| Q3 2021 | $12,327,000 | -25.6% | 20,590,000 | -17.6% | 0.18% | +36.4% |
| Q2 2021 | $16,578,000 | – | 25,000,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |